View Older Stories View More Recent Stories

May 19, 2023 06:00AM 2seventy bio Presents Late-Breaking Results for SC-DARIC33, an Investigational CD33-Targeting CAR T in Pediatric and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia
May 17, 2023 07:18AM 2seventy bio (TSVT) Presents Broad Range of New Data Highlighting Novel Approaches Across its Cell Therapies Portfolio
May 17, 2023 07:17AM 2seventy bio Presents Broad Range of New Data Highlighting Novel Approaches Across its Cell Therapies Portfolio
May 11, 2023 12:37PM 2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023
May 3, 2023 04:05PM 2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
May 2, 2023 04:37PM 2seventy bio to Present New Preclinical and Clinical Data from Broad Portfolio of Investigational Cell Therapies at the ASGCT 26th Annual Meeting
May 1, 2023 07:05AM 2seventy bio (TSVT) and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15M Preclinical Milestone
May 1, 2023 07:00AM 2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program
Apr 28, 2023 08:30AM 2seventy bio to Report First Quarter 2023 Financial Results on May 3, 2023
Apr 27, 2023 06:59AM Bristol Myers Squibb Reports First Quarter Financial Results for 2023
Apr 17, 2023 07:09AM Bristol-Myers (BMY), 2seventy (TSVT) Announces Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed R/R Multiple Myeloma
Apr 17, 2023 06:59AM Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma
Mar 16, 2023 04:05PM 2seventy bio Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Progress
Mar 8, 2023 08:30AM 2seventy bio Announces Appointment of Wei Lin, M.D. to Board of Directors
Mar 3, 2023 07:00AM 2seventy bio to Participate in 43rd Annual TD Cowen Health Care Conference
Feb 10, 2023 11:15AM Bristol-Myers (BMY), 2seventy (TSVT) Announces Abecma Reduced Risk of Disease Progression, Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for R/R Multiple Myeloma Based on Results f
Feb 10, 2023 11:13AM Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Resul
Feb 1, 2023 07:30AM 2seventy bio to Participate in Upcoming Investor Conferences
Jan 9, 2023 08:03AM 2seventy bio (TSVT) Provides Company Outlook for 2023
Jan 9, 2023 08:00AM 2seventy bio Provides Company Outlook for 2023
Jan 6, 2023 01:03PM Biotech Industry Leaders Join Deep Genomics Board of Directors and Scientific Advisory Board
Jan 6, 2023 09:11AM 2seventy bio (TSVT) Announces Expanded Translational Collaboration with Regeneron (REGN) to Develop New Cell Therapy-Based Combinations for Solid Tumors
Jan 6, 2023 09:11AM 2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid Tumors
Nov 7, 2022 04:05PM 2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
Nov 3, 2022 09:06AM 2seventy bio to Present Data from KarMMa-2 Study of Abecma (idecabtagene vicleucel) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
Oct 27, 2022 07:00AM 2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies
Oct 26, 2022 03:36AM Bristol-Myers Squibb (BMY) Reports Q3 Revenue of $11.22B, EPS of $1.99
Oct 25, 2022 07:31PM Bristol Myers Squibb Reports Third Quarter Financial Results for 2022 
Sep 7, 2022 07:04AM 2seventy bio (TSVT) Announces Plans to Initiate KarMMa-9 Study of Abecma (idecabtagene vicleucel) in Newly Diagnosed Multiple Myeloma Patients
Sep 7, 2022 07:00AM 2seventy bio Announces Plans to Initiate KarMMa-9 Study of Abecma (idecabtagene vicleucel) in Newly Diagnosed Multiple Myeloma Patients
Aug 31, 2022 07:30AM 2seventy bio to Participate in Upcoming Investor Conferences
Aug 10, 2022 06:50AM 2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
Aug 10, 2022 06:47AM Bristol-Myers Squibb (BMY) and 2seventy (TSVT) Report Positive Topline Results from KarMMa-3 Trial
Aug 10, 2022 06:45AM Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in
Aug 3, 2022 07:30AM 2seventy bio to Participate in Upcoming Investor Conferences
Jun 6, 2022 07:30AM 2seventy bio to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
May 12, 2022 04:05PM 2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
Apr 8, 2022 04:16PM 2seventy bio (TSVT) Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, at the AACR
Apr 8, 2022 04:15PM 2seventy bio Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, at the AACR Annual Meeting
Apr 7, 2022 07:30AM 2seventy bio to Participate in CG Horizons in Oncology Virtual Conference
Mar 22, 2022 07:00AM 2seventy bio Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress
Mar 16, 2022 07:07AM 2seventy bio (TSVT) Announces 13.93M Share Private Placement at $12.20/sh
Mar 16, 2022 07:06AM 2seventy bio Secures $170 Million in Private Placement Equity Financing
Feb 14, 2022 07:30AM 2seventy bio Announces Key Management Appointments
Feb 14, 2022 07:00AM 2seventy bio to Participate in Upcoming Healthcare Conferences
Jan 11, 2022 07:02AM 2seventy bio (TSVT) Announces Key Milestones and Business Updates for 2022
Jan 11, 2022 07:00AM 2seventy bio Shares Key Milestones and Business Updates for 2022
Jan 6, 2022 07:00AM 2seventy bio Announces Expanded Collaboration Agreement With Novo Nordisk to Continue Development of in vivo Gene Editing Approach
Dec 13, 2021 06:15PM  2seventy bio Presents Data Across Multiple Cell Therapy Programs at ASH 2021 Annual Meeting
Dec 1, 2021 07:00AM 2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
View More Recent Stories View Older Stories